|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...116117118119120121122123124125126...10651066» |
- Sarclisa (isatuximab-irfc) / Sanofi
First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1523;
P=N/A
Most of the pts continued to receive isatuximab after the end of CUP. More data on the efficacy and safety of isatuximab in the real-world setting will be generated within the open IONA-MM registry (NCT04458831) and IMAGE study.
- Elrexfio (elranatamab) / Pfizer, Darzalex (daratumumab) / J&J
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1520;
P2, P3
More data on the efficacy and safety of isatuximab in the real-world setting will be generated within the open IONA-MM registry (NCT04458831) and IMAGE study. Key exclusion criteria: smoldering MM; monoclonal gammopathy of undetermined significance (MGUS); Waldenstr
- Empliciti (elotuzumab) / AbbVie, BMS
Identification of a reliable study endpoint for bone remineralization in sequential CT scans of patients with newly diagnosed multiple myeloma after six cycles of E-KRd (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1519;
The sum of lesion sizes can be used as a study endpoint to characterize bone remineralization. Six cycles of E-KRd treatment induce substantial bone remineralization in osteolytic lesions in patients with newly diagnosed MM.
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Triple autologous stem cell transplantation for primary CNS lymphoma (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1492;
Six cycles of E-KRd treatment induce substantial bone remineralization in osteolytic lesions in patients with newly diagnosed MM. Salvage therapy with the R-DeVIC regimen (rituximab 375 mg/m
- Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Intraspinal extramedullary hematopoietic mass (EMH) in a luspatercept-treated patient with transfusion-dependent beta-thalassemia (TDT) (Y1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1480;
Of note, luspatercept-associated EMHs may also occur after prolonged time (>96 weeks). Therefore, screening for (spinal) EMHs in both, NTDT and TDT patients, by MRI scan prior to treatment and during follow-up - even in non-symptomatic patients - may potentially reduce associated complications allowing for early intervention.
- dexamethasone / Generic mfg.
ROR-1 CAR-T cells with CRISPR/Cas9-mediated glucocorticoid receptor knockout exert potent antitumor efficacy in advanced adrenocortical carcinoma (X2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1367;
Our data show that ROR-1 is commonly and homogenously overexpressed in human ACC specimen. ROR-1 CART exert potent antitumor efficacy, which can be maintained by hGR KO in the presence of glucocorticoid excess in vitro .
- Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Complete remission after sequential Inotuzumab, Blinatumomab and chemotherapy with concurrent donor lymphocyte infusions in relapsed pre-B-ALL after allogeneic stem cell transplantation. (Hall F) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1098;
A cytoreductive therapy with Doxorubicin 45mg/m 2 , Vincristine 2mg and a second DLI-application (1.5x10 7 CD3+cells/kg) followed in month four...Temporary, a hepatic GvHD grade I was observed, which was treated with budesonide orally...In conclusion, our case demonstrates that co-administration of DLI, InO, Blina and chemotherapy is feasible without severe GvHD. Given these promising results, this
- Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for Preventing Chemotherapy-induced Nausea and Vomiting (CINV) in Patients at Increased Emetic Risk Receiving Moderately Emetogenic Chemotherapy (Hall 4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1066;
P4
Background: In patients receiving moderately emetogenic chemotherapy (MEC), antiemetic guidelines lack evidence to recommend an NK 1 receptor antagonist (RA) for all patients; therefore, they endorse a 5-HT 3 RA + dexamethasone (DEX)...A generalized linear model will analyze CR over 3 cycles of MEC with logit link function, binomial distribution, and with study treatment, carboplatin use, and the country as factors...Enrollment is open; as of April 26, 2023, 287 patients have been randomized. In Germany, 96 of 100 patients have been enrolled by five study centres.
- Darzalex (daratumumab) / J&J
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1023;
P3
In Germany, 96 of 100 patients have been enrolled by five study centres. In this subgroup analysis of MAIA, D-Rd improved PFS, ORR, and MRD-negativity rates versus Rd across clinically important subgroups, Results for these clinically important subgroups provide confidence in using D-Rd across all pt types, supporting D-Rd as a standard of care for transplant-ineligible pts with NDMM.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Blenrep (belantamab mafodotin-blmf) / GSK
Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma: Study Concept of the investigator-initiated Phase I/IIa BELI(E)VE-Trial (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1022;
The BELI(E)VE trial is a unique personalized targeted treatment approach for t(11;14) RRMM. It will evaluate for the first time safety and efficacy of the combination treatment of VEN and BelaMaf (
- Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
A Systematic Review and Meta-Analysis of Randomized Data on Monoclonal Antibodies added to Proteasome Inhibitor or Immunomodulatory Backbones in Patients with Relapsed and Refractory Multiple Myeloma (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1020;
MAb triplet regimens available for len-ref patients with at least one prior therapy generally outperform doublet regimens regarding overall survival. As an alternative to PI-based regimens, DPd presents a valuable treatment option, given its explicit indication for 2 nd TL len-ref patients.
- Ninlaro (ixazomib) / Takeda
Ixazomib/Lenalidomide/Dexamethasone (IRd) in relapsed refractory Multiple Myeloma (RRMM) - retrospective real-world data from Germany and comparison to literature (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1017;
As an alternative to PI-based regimens, DPd presents a valuable treatment option, given its explicit indication for 2 nd TL len-ref patients. These German data confirm findings of other real-world analyses: as expected our pts were more heavily pretreated than pts in TOURMALINE-MM1 (median of 2 (1-5) vs. 1 (1-3) prior lines) and in routine clinical practice nearly all pts were PI-pretreated (95-100% vs. 69% in TOURMALINE-MM1).
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Efficacy, Survival and Safety of Selinexor, Bortezomib and Dexamethasone (SVd) in Patients with Lenalidomide-Refractory Multiple Myeloma: Subgroup Data from the BOSTON Trial (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1016;
P3
Subgroup data from the BOSTON trial show a statistically significant and clinically meaningful improvement in OS and PFS and higher ORR and VGPR or better with SVd vs Vd in LEN-refractory RRMM pts. The statistically significant 47% reduction in risk of death with SVd vs Vd shows an advantage of having a regimen built on 2 drugs with different mechanisms of action in this difficult-to-treat population.
- Blenrep (belantamab mafodotin-blmf) / GSK
DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) (Hall G) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1011;
P3
However, median PFS was longer for belamaf monotherapy, and belamaf induced deeper, more durable responses than Pd. No new safety signals were observed.
- Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
Retrospective analysis of the pre-apheresis, bridging and post-CAR-T phase in relapsed/refractory multiple myeloma reveals novel markers associated with clinical course and outcome after anti-BCMA CAR T-cell therapy (Hall A) - Sep 30, 2023 - Abstract #DGHO2023DGHO_822;
However, CTX-intense regimens appear to be associated with an increased risk for prolonged cytopenias and infections after CAR T-cell therapy. The EASIX score could improve risk stratification.
- Carvykti (ciltacabtagene autoleucel) / J&J
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma (Hall A) - Sep 30, 2023 - Abstract #DGHO2023DGHO_819;
P3
Introduction: CARTITUDE-4 is a global, phase 3, randomized, controlled trial (NCT04181827) of cilta-cel, a dual-binding, BCMA-targeting CAR-T cell therapy, vs standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in lenalidomide (len)-refractory patients (pts). A single cilta-cel infusion significantly improved PFS vs SOC in len-refractory pts with 1
- Jakafi (ruxolitinib) / Novartis, Incyte, Kineret (anakinra) / SOBI
Case of an adult onset of familial hemophagocytic lymphohistiocytosis (HLH) simultaneously to T-cell large granular lymphocyte leukemia (X2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_672;
This case illustrates that fHL can occur in adults and that the family history is of great importance as other individuals can be affected. Hematological malignancies are more frequent in patients with hypomorphic cytotoxicity defects.
- dexamethasone / Generic mfg., cyclosporin A microemulsion / Generic mfg.
Late-onset primary hemophagocytic lymphohistiocytosis leading to the diagnosis of Griscelli Syndrome Type 2 with phenotypically inapparent partial albinism in a young woman (X2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_669;
Exceptional about this case is the unusually late onset of a first life-threatening HLH episode and no clinically overt albinism in a patient with GS 2. This patient case highlights the fact that genetic testing for very rare inherited immunodeficiency-associated syndromes should be included in the workup of patients with unclear HLH.
- Keytruda (pembrolizumab) / Merck (MSD)
Long-term complete remission in a patient with EBV-triggered hemophagocytic lymphohistiocytosis and Hodgkin (X2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_668;
This patient case highlights the fact that genetic testing for very rare inherited immunodeficiency-associated syndromes should be included in the workup of patients with unclear HLH. We therefore started dexamethasone aiming to restore liver function...At this time, an EBV reactivation was diagnosed, which we treated with addition of Rituximab...Brentuximab was added as HL therapy, but patient
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Succesfull, non-surgical treatment of severe Stauffer syndrome by with sequential, overlapping anti-inflammatory and antineoplastic therapy. (X2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_666;
We thus initiated dual checkpoint inhibition with nivolumab and ipilimumab, following which the dexamethasone could be tapered by 4 mg per week. To the best of our knowledge, this is the first reported case of successful treatment of Stauffer syndrome with sequential concomitant anti-inflammatory and antineoplastic treatment.
- Keytruda (pembrolizumab) / Merck (MSD)
Sustained complete remission with oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab (Hall B) - Sep 30, 2023 - Abstract #DGHO2023DGHO_568;
Sustained CR was achieved over 9 months after initiation of MEPED therapy. Further studies on a larger patient cohort should be performed.
- Darzalex (daratumumab) / J&J
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_564;
D-Rd also achieved a nearly3-fold higher MRD-negativity rate and a ?4-fold higher ?12-month sustained MRD-negativity rate versus Rd. No new safety concerns were observed with longer follow-up.
- Sarclisa (isatuximab-irfc) / Sanofi
Expression-linked and R-ISS-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS) (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_563;
The primary objective is to show non-inferiority of the experimental arm compared to the control arm with standard of care regarding the rate of patients with minimal residual disease (MRD) negativity combined with at least a complete remission response according to IMWG criteria at week 40 after start of induction therapy (18 weeks after randomization). Furthermore, we aim to detect possible differences in MRD negativity at specific points of time and to characterize both arms with respect to OS and PFS since randomization, PFS during second-line treatment since relapse, time to next treatment, and overall response rate.
- Blenrep (belantamab mafodotin-blmf) / GSK
A phase I study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: an interim analysis of DREAMM-9 (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_560;
P1
DREAMM-9 aims to evaluate belamaf plus bortezomib, lenalidomide, and dexamethasone (VRd) in adult patients with transplant-ineligible newly diagnosed multiple myeloma, and establish the recommended dose for future development of belamaf combination therapies in the first-line setting. Belamaf plus VRd has no new safety signals, and provides early and deep antimyeloma responses in patients with transplant-ineligible newly diagnosed multiple myeloma.
- Blenrep (belantamab mafodotin-blmf) / GSK
Patient (pt)-reported outcomes in pts with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin (belamaf) vs pomalidomide/low dose dexamethasone (Pd) in the phase III, open-label, randomized, multicenter DREAMM-3 study (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_558;
P3
Pts had small mean improvements in disease pain across both arms. Despite deterioration in VRF for a majority of patients on belamaf, both physical functioning and global health status improved for the tx arm over time.
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Selinexor, bortezomib, and dexamethasone in patients with previously treated multiple myeloma (MM): updated results of BOSTON trial by prior therapies (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_551;
P3
There is a statistically significant & clinically meaningful ~20 mo mPFS improvement of SVd over Vd in RRMM pts with no prior exposure to PI and bortezomib as well as a significant ~10 mo PFS improvement in pts with 1 prior LOT. These outcomes emphasize the synergy between selinexor and bortezomib and importance of a double mode of action switch, supporting SVd use in PI-na
- Empliciti (elotuzumab) / AbbVie, BMS
Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_516;
P3
E-KRd pts experienced slightly more TEAEs most of which were hematotoxicity. To the best of our knowledge, this is the first study to show a benefit for the addition of elotuzumab to a front-line regimen at an early point.
- mezigdomide (CC-92480) / BMS
Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_512;
P1/2
To the best of our knowledge, this is the first study to show a benefit for the addition of elotuzumab to a front-line regimen at an early point. Methods : Pts had RRMM, 2
- Sarclisa (isatuximab-irfc) / Sanofi
Planned Interim Analysis of the GMMG-CONCEPT Trial investigating Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_511;
P2
Pts undergo 6 cycles (x) of Isa-KRd induction, high-dose melphalan for TE pts or 2x Isa-KRd for TNE pts, 4x Isa-KRd CONS and Isa-KR maintenance. The CONCEPT trial investigating Isa-KRd for HR NDMM in TE and TNE pts showed high MRD(-) rates after CONS in this difficult-to-treat population and underlines the importance of optimized quadruplet treatment particularly in HR NDMM.
- Sarclisa (isatuximab-irfc) / Sanofi
Investigation of cardiac biomarkers and association with clinical course under treatment with a carfilzomib containing quadruplet regimen in high-risk newly diagnosed multiple myeloma patients: Results from the correlative program of the GMMG-CONCEPT trial (X5) - Sep 30, 2023 - Abstract #DGHO2023DGHO_187;
P2
Increased NT-proBNP is not predictive of CVAE at any time point during K-based treatment for high-risk MM. NT-proBNP is a more robust cardiac biomarker during the later course of K-based anti-MM treatment but not at initial diagnosis.
- | triamcinolone acetonide / Generic mfg., enalapril / Generic mfg.
Journal: Safety and efficacy of intralesional injection of enalapril versus triamcinolone acetonide in the treatment of keloids. (Pubmed Central) - Sep 30, 2023
Enalapril could be a safe alternative to steroids in the treatment of keloid and hypertrophic scars. Further studies on enalapril are needed on a large sample of patients with further focus on the mechanism of this innovative drug.
- | dexamethasone / Generic mfg.
Journal: Lithium-induced subacute diencephalic angio endotheliopathy. (Pubmed Central) - Sep 30, 2023
The patient deceased one month after discharge, mainly due to Diabetes Insipidusassociated hypernatremia. Dissecting the "Pandora's box" represented by complex MRI findings (SDAE and sinus thrombosis) in lithium-induced neurotoxicity is fundamental in timely recognizing this threating but potentially reversible clinical picture.
- | dexamethasone / Generic mfg.
Journal: Exposure to low-intensity noise exacerbates nonalcoholic fatty liver disease by activating hypothalamus pituitary adrenal axis. (Pubmed Central) - Sep 30, 2023
In vivo (n?=?5) and in vitro models challenged with dexamethasone (DEX) were used to verify the role of hypothalamus pituitary adrenal (HPA) axis activation in hepatic lipid metabolism...Thus, three-month exposure to 75?dB SPL noise was sufficient to exacerbate NAFLD progress in mice, where activation of HPA axis played a critical role. Depression played an intermediate role and contributed to HPA axis activation up-stream of the exacerbation.
- | MK-2206 / Merck (MSD)
Journal: Neuroligin-3 activates Akt-dependent Nrf2 cascade to protect osteoblasts from oxidative stress. (Pubmed Central) - Sep 30, 2023
At last, we showed that NLGN3 mRNA and protein expression was significantly downregulated in necrotic bone tissues of dexamethasone-taken patients. Taken together, NLGN3 activated Akt-dependent Nrf2 cascade to protect osteoblasts from oxidative stress.
- | bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Journal: The efficacy and safety of bortezomib, pomalidomide and dexamethasone regimen in the treatment of relapsed/refractory multiple myeloma (Pubmed Central) - Sep 29, 2023
Taken together, NLGN3 activated Akt-dependent Nrf2 cascade to protect osteoblasts from oxidative stress. No abstract available
- | dexamethasone / Generic mfg.
Journal: Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. (Pubmed Central) - Sep 29, 2023
Medical records of patients with relapsed or refractory DLBCL receiving second-line ESHAP or DICE chemotherapy with or without rituximab from January 2007 to November 2022 were retrospectively reviewed...Efficacy between ESHAP and DICE regimens as salvage chemotherapy for relapsed or refractory DLBCL was not significantly different in terms of two-year PFS, two-year OS and ORR. DICE regimen had less renal AE than ESHAP.
- || triamcinolone acetonide / Generic mfg.
Retrospective data, Review, Journal: High- versus Low-dose Steroid Injection for Adhesive Capsulitis (Frozen Shoulder): A Systematic Review and Meta-analysis. (Pubmed Central) - Sep 29, 2023
Therefore, considering the side effects of high-dose steroids, starting with low-dose steroids is recommended. However, further studies are needed to establish exact protocols according to disease severity.
- || dexamethasone / Generic mfg.
Clinical, Retrospective data: Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial. (Pubmed Central) - Sep 29, 2023
However, further studies are needed to establish exact protocols according to disease severity. No abstract available
- | dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
Preclinical, Journal, IO biomarker: Toxicity evaluation of synthetic glucocorticoids against breast cancer cell lines MDA-MB-231, MCF-7 and human embryonic kidney HEK293. (Pubmed Central) - Sep 29, 2023
Additionally, Hydrocortisone downregulated the expression of anti-apoptotic Bcl-2 proteins. In summary, our findings underscore the safety of clinical doses in terms of cell toxicity meanwhile increased concentration were showing an anti-proliferative potential of Hydrocortisone, particularly against adenocarcinoma breast cancer cell lines.
- | abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
New P2 trial, Metastases: NU 23U08: Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone (clinicaltrials.gov) - Sep 29, 2023
P2, N=150, Not yet recruiting, Sponsor: Northwestern University
- | dexamethasone / Generic mfg.
Journal: Capsular phimosis with intraocular lens tilt and decentration. (Pubmed Central) - Sep 28, 2023
A 34-year-old woman with quiescent bilateral intermediate uveitis maintained on once-daily dexamethasone 0.1% eyedrops, complicated by left cataract and glaucoma controlled with a single antiglaucoma medication, presented for cataract surgery...Discuss how you would manage this problem, explaining your decisions. How would you be able to avoid the same problem when operating on her fellow eye?
- | hydrocortisone / Generic mfg.
Journal: Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency. (Pubmed Central) - Sep 28, 2023
These results suggest that DR-HC is associated with less bone-related complications compared to C-GC in patients with PAI. Moreover, TBS seems to play a pivotal role in the mediation of the relationship between glucocorticoid treatment regimens and fracture risk.
- | 5-fluorouracil / Generic mfg.
Journal: Efficacy of press needle treatment in reducing chemotherapy-induced nausea, vomiting, and retching gastrointestinal cancer patients: A (Pubmed Central) - Sep 28, 2023
The control group received 5-hydroxytryptamine-3 (5-HT3) antagonists and dexamethasone 30 min before chemotherapy, followed by dexamethasone on days 2 and 3 after chemotherapy...Chinese Clinical Trial Registry (No. ChiCTR1900024554).
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial completion date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Sep 28, 2023
P3, N=5937, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
ChiCTR1900024554). Trial completion date: Jan 2024 --> Sep 2024
- | idasanutlin (RG7388) / Roche, Ninlaro (ixazomib) / Takeda
Trial completion date, Combination therapy: Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=33, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Jan 2024 --> Sep 2024 Trial completion date: Dec 2023 --> Dec 2024
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion date, Trial primary completion date, Post-transplantation: Methods of T Cell Depletion Trial (MoTD) (clinicaltrials.gov) - Sep 28, 2023
P2, N=400, Recruiting, Sponsor: University of Birmingham
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Jun 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Jan 2026
- | lenalidomide / Generic mfg.
Trial completion date, Combination therapy, IO biomarker: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) (clinicaltrials.gov) - Sep 28, 2023
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Jan 2026 Trial completion date: Dec 2026 --> Dec 2025
- | dexamethasone / Generic mfg.
Journal: Insights into the antiosteoporotic mechanism of the soy-derived isoflavone genistein: Modulation of the Wnt/beta-catenin signaling. (Pubmed Central) - Sep 28, 2023
and ?. These data suggest that genistein could induce bone remodeling through Wnt/?-catenin pathway activation.
- | risedronate / Generic mfg.
Preclinical, Journal: Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement. (Pubmed Central) - Sep 28, 2023
The prepared nanoparticles were evaluated for their bone-targeting potential by inducing osteoporosis in female Wistar rats via oral administration of Dexona (dexamethasone sodium phosphate). A stability analysis was also carried out according to ICH guidelines (Q1AR2), and it was found that RIS-HA-TCS-mPEG was more stable than RIS-HA-TCS at 25
- | dexamethasone / Generic mfg.
Journal: Interpenetrating Polymer Networks of Poly(2-hydroxyethyl methacrylate) and Poly(N, N-dimethylacrylamide) as Potential Systems for Dermal Delivery of Dexamethasone Phosphate. (Pubmed Central) - Sep 28, 2023
Energy-dispersive X-ray (EDX) spectroscopy shows an even distribution of DXP within the IPN structure. The DXP release follows Fickian diffusion with ~70% of DXP released in 24 h. This study demonstrates the potential of the newly developed IPNs for the dermal delivery of DXP.